Loading
Sitneprotafib is an experimental small-molecule drug from Allist Pharmaceuticals in phase 3 trials for non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, with its target not yet stated publicly.
Sitneprotafib (JAB-3312) is a small-molecule drug developed by Allist Pharmaceuticals. The sponsor describes its target as SHP2, which OnCo does not yet have a target page for. The sponsor states: JAB-3312 (sitneprotafib) is a second-generation allosteric SHP2 inhibitor developed by Jacobio, described as having more potent anti-tumour activity than earlier SHP2 inhibitors; combined with the KRAS G12C inhibitor glecirasib (JAB-21822) in a registrational phase 3 trial for first-line KRAS G12C-mutated NSCLC. ClinicalTrials.gov describes the intervention as: JAB-3312 administered orally as a tablet or capsule. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06416410 (JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation), in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma. The largest, NCT06416410, plans to enrol 392 participants with primary completion expected 2029-09-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
JAB-3312 (sitneprotafib) is a second-generation allosteric SHP2 inhibitor developed by Jacobio, described as having more potent anti-tumour activity than earlier SHP2 inhibitors; combined with the KRAS G12C inhibitor glecirasib (JAB-21822) in a registrational phase 3 trial for first-line KRAS G12C-mutated NSCLC. Connects to SHP2 (PTPN11).
1.Sitneprotafib slips into a pocket on SHP2 (PTPN11).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sitneprotafib" OR ABSTRACT:"Sitneprotafib" OR TITLE:"JAB-3312" OR ABSTRACT:"JAB-3312") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sitneprotafib, not a curated reading list.
Shares JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation, Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation, SHP2 (PTPN11), Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.